Blume-Jensen Peter 4
4 · Acrivon Therapeutics, Inc. · Filed Feb 24, 2026
Research Summary
AI-generated summary of this filing
Acrivon (ACRV) CEO Peter Blume-Jensen Surrenders 14,265 Shares for Taxes
What Happened
- Peter Blume-Jensen, President, CEO and a director of Acrivon Therapeutics (ACRV), had 14,265 shares disposed on 2026-02-21 as shares were withheld to satisfy tax withholding on vested restricted stock units (RSUs). The withholding was recorded at $1.53 per share for a total value of approximately $21,825. This was a tax-withholding/cashless disposition (routine), not an open-market sale.
Key Details
- Transaction date: 2026-02-21; per-share price used for withholding: $1.53; total value ≈ $21,825.
- Transaction code: F — tax withholding to satisfy mandatory tax obligations on vesting (see footnote F1).
- Shares owned after the withholding: not specified in the provided excerpt.
- Filing date: Form 4 filed 2026-02-24 (no timeliness flag provided in the excerpt).
- Footnotes: F1 confirms shares were withheld by the issuer for taxes. F2/F3 note certain securities are held by each spouse (Dr. Blume-Jensen and Dr. Kristina Masson) with mutual disclaimers of beneficial ownership except for pecuniary interest.
Context
- Tax-withholding dispositions are common when RSUs vest and generally reflect administrative settlement rather than a vote on company prospects. This transaction does not represent an open-market sale by the CEO.
Insider Transaction Report
Form 4
Blume-Jensen Peter
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
[F1][F2]2026-02-21$1.53/sh−14,265$21,825→ 2,080,204 total
Holdings
- 314,127(indirect: See Footnote)
Common Stock
[F3]
Footnotes (3)
- [F1]Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
- [F2]These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- [F3]These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.